Does the media prefer CADL or ADPT?

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 4 mentions for Candel Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Candel Therapeutics' score of 0.52 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher earnings and valuation, CADL or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is CADL or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Enliven Therapeutics N/A -21.04% -20.41%

Does the media prefer CADL or ELVN?

In the previous week, Enliven Therapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 5 mentions for Enliven Therapeutics and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.52 beat Enliven Therapeutics' score of 0.08 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RARE or CADL?

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.52 beat Ultragenyx Pharmaceutical's score of 0.47 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CADL or IMNM more profitable?

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Immunome N/A -51.15% -47.32%

Does the media favor CADL or IMNM?

In the previous week, Candel Therapeutics had 1 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Candel Therapeutics and 3 mentions for Immunome. Candel Therapeutics' average media sentiment score of 0.52 beat Immunome's score of 0.25 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, KOD or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is KOD or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to KOD or CADL?

In the previous week, Candel Therapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Candel Therapeutics and 3 mentions for Kodiak Sciences. Candel Therapeutics' average media sentiment score of 0.52 beat Kodiak Sciences' score of 0.51 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Candel Therapeutics (CADL) Competitors

$8.50 -0.01 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.63 +0.13 (+1.56%)

As of 07:53 PM Eastern

Compare

CADL vs. ADPT, ELVN, RARE, IMNM, and KOD

Should you buy Candel Therapeutics stock or one of its competitors? MarketBeat compares Candel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Candel Therapeutics include Adaptive Biotechnologies (ADPT), Enliven Therapeutics (ELVN), Ultragenyx Pharmaceutical (RARE), Immunome (IMNM), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Candel Therapeutics (NASDAQ:CADL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Candel Therapeutics currently has a consensus target price of $18.00, indicating a potential upside of 111.76%. Adaptive Biotechnologies has a consensus target price of $19.57, indicating a potential upside of 17.19%. Given Candel Therapeutics' higher probable upside, research analysts plainly believe Candel Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Candel Therapeutics. MarketBeat recorded 10 mentions for Adaptive Biotechnologies and 4 mentions for Candel Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.51 beat Candel Therapeutics' score of 0.52 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Candel Therapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Adaptive Biotechnologies	$276.98M	9.65	-$59.50M	-$0.33	N/A

Summary

Adaptive Biotechnologies beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Enliven Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Enliven Therapeutics had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 5 mentions for Enliven Therapeutics and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.52 beat Enliven Therapeutics' score of 0.08 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics' return on equity of -21.04% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Candel Therapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Candel Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 111.76%. Enliven Therapeutics has a consensus target price of $61.80, suggesting a potential upside of 83.76%. Given Candel Therapeutics' higher probable upside, equities analysts plainly believe Candel Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Candel Therapeutics and Enliven Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

In the previous week, Ultragenyx Pharmaceutical had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 8 mentions for Ultragenyx Pharmaceutical and 4 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.52 beat Ultragenyx Pharmaceutical's score of 0.47 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Candel Therapeutics' return on equity of -60.42% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Candel Therapeutics	N/A	-60.42%	-41.33%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ultragenyx Pharmaceutical presently has a consensus price target of $59.56, indicating a potential upside of 175.88%. Candel Therapeutics has a consensus price target of $18.00, indicating a potential upside of 111.76%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Candel Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.16	-$575M	-$6.11	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market.

Summary

Ultragenyx Pharmaceutical beats Candel Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Immunome?

Candel Therapeutics (NASDAQ:CADL) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Candel Therapeutics has higher earnings, but lower revenue than Immunome. Candel Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Immunome	$6.94M	303.69	-$212.39M	-$2.38	N/A

In the previous week, Candel Therapeutics had 1 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Candel Therapeutics and 3 mentions for Immunome. Candel Therapeutics' average media sentiment score of 0.52 beat Immunome's score of 0.25 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 111.76%. Immunome has a consensus target price of $33.17, suggesting a potential upside of 78.22%. Given Candel Therapeutics' higher possible upside, equities research analysts clearly believe Candel Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immunome's return on equity of -51.15% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Immunome	N/A	-51.15%	-47.32%

Candel Therapeutics has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market. Comparatively, Immunome has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Summary

Candel Therapeutics and Immunome tied by winning 7 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Candel Therapeutics	N/A	-60.42%	-41.33%

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Kodiak Sciences currently has a consensus target price of $42.14, indicating a potential upside of 42.33%. Candel Therapeutics has a consensus target price of $18.00, indicating a potential upside of 111.76%. Given Candel Therapeutics' higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, Candel Therapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Candel Therapeutics and 3 mentions for Kodiak Sciences. Candel Therapeutics' average media sentiment score of 0.52 beat Kodiak Sciences' score of 0.51 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market.

Summary

Candel Therapeutics beats Kodiak Sciences on 7 of the 12 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$623.53M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-8.67	18.61	23.92	23.74
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	8.95	8.04	10.28	6.78
Net Income	-$38.18M	$23.89M	$3.57B	$337.51M
7 Day Performance	-0.12%	-5.97%	-1.43%	-2.72%
1 Month Performance	1.80%	2.78%	3.27%	1.87%
1 Year Performance	40.73%	36.26%	23.37%	26.60%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.9446 of 5 stars	$8.50 -0.1%	$18.00 +111.8%	+40.9%	$623.53M	N/A	N/A	60
ADPT Adaptive Biotechnologies	3.1633 of 5 stars	$15.23 +0.5%	$19.57 +28.5%	+67.5%	$2.42B	$295.41M	N/A	790	Positive News Insider Trade
ELVN Enliven Therapeutics	2.8426 of 5 stars	$37.51 -5.2%	$58.40 +55.7%	+67.4%	$2.41B	N/A	N/A	50	News Coverage
RARE Ultragenyx Pharmaceutical	2.8497 of 5 stars	$22.85 -4.6%	$59.56 +160.7%	-41.1%	$2.36B	$670M	N/A	1,371	Analyst Upgrade Gap Up
IMNM Immunome	3.6302 of 5 stars	$20.78 -4.8%	$33.17 +59.6%	+103.5%	$2.35B	$4.02M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. ADPT, ELVN, RARE, IMNM, and KOD

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Candel Therapeutics compare to Enliven Therapeutics?

Summary

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Candel Therapeutics compare to Immunome?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. ADPT, ELVN, RARE, IMNM, and KOD

How does Candel Therapeutics compare to Adaptive Biotechnologies?

Do analysts prefer CADL or ADPT?

Do institutionals and insiders believe in CADL or ADPT?

Is CADL or ADPT more profitable?

Does the media prefer CADL or ADPT?

Which has more risk and volatility, CADL or ADPT?

Which has stronger earnings and valuation, CADL or ADPT?

Summary

How does Candel Therapeutics compare to Enliven Therapeutics?

Does the media prefer CADL or ELVN?

Is CADL or ELVN more profitable?

Which has more risk & volatility, CADL or ELVN?

Do institutionals & insiders have more ownership in CADL or ELVN?

Which has higher earnings and valuation, CADL or ELVN?

Do analysts prefer CADL or ELVN?

Summary

How does Candel Therapeutics compare to Ultragenyx Pharmaceutical?

Does the media prefer RARE or CADL?

Is RARE or CADL more profitable?

Do institutionals and insiders have more ownership in RARE or CADL?

Do analysts recommend RARE or CADL?

Which has higher valuation & earnings, RARE or CADL?

Which has more risk & volatility, RARE or CADL?

Summary

How does Candel Therapeutics compare to Immunome?

Which has stronger earnings & valuation, CADL or IMNM?

Does the media favor CADL or IMNM?

Do analysts rate CADL or IMNM?

Do insiders and institutionals have more ownership in CADL or IMNM?

Is CADL or IMNM more profitable?

Which has more volatility and risk, CADL or IMNM?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Is KOD or CADL more profitable?

Do institutionals & insiders believe in KOD or CADL?

Which has higher valuation & earnings, KOD or CADL?

Do analysts recommend KOD or CADL?

Does the media refer more to KOD or CADL?

Which has more volatility and risk, KOD or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools